These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2475694)

  • 1. Calcium antagonists in the treatment of essential hypertension: review of international studies.
    Clement DL
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S7-11. PubMed ID: 2475694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lercanidipine : a review of its efficacy in the management of hypertension.
    Bang LM; Chapman TM; Goa KL
    Drugs; 2003; 63(22):2449-72. PubMed ID: 14609358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension.
    Muijsers RB; Curran MP; Perry CM
    Drugs; 2002; 62(17):2539-67. PubMed ID: 12421112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The place of the calcium antagonist verapamil in antihypertensive therapy.
    Bühler FR; Hulthén UL; Kiowski W; Müller FB; Bolli P
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S350-7. PubMed ID: 6184567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium antagonists and beta blockers in the control of mild to moderate systemic hypertension, with particular reference to verapamil and propranolol.
    Singh BN; Rebanal P; Piontek M; Nademanee K
    Am J Cardiol; 1986 Feb; 57(7):99D-105D. PubMed ID: 2869676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring].
    Jasiński T; Janicki K; Klima M; Pieniazek W; Bednarz S
    Przegl Lek; 1996; 53(2):73-7. PubMed ID: 8754325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium antagonists, firstline partners for betablockers in hypertension.
    Bühler FR
    Z Kardiol; 1984; 73 Suppl 2():95-9. PubMed ID: 6152093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of calcium antagonists in hypertension: update 1986.
    Lund-Johansen P
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S29-35. PubMed ID: 2455135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What, if anything, is controversial about calcium antagonists?
    Messerli FH
    Am J Hypertens; 1996 Dec; 9(12 Pt 2):177S-181S. PubMed ID: 8968430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the hypotensive effects of calcium antagonists.
    Erne P; Bolli P; Bertel O; Hulthen UL; Kiowski W; Muller FB; Buhler F
    Hypertension; 1983; 5(4 Pt 2):II97-102. PubMed ID: 6345378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium antagonism--a new concept for treating essential hypertension.
    Müller FB; Bolli P; Erne P; Kiowski W; Bühler FR
    Am J Cardiol; 1986 Feb; 57(7):50D-53D. PubMed ID: 3006467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course for blood pressure lowering of dihydropyridine calcium channel blockers.
    Ghamami N; Chiang SH; Dormuth C; Wright JM
    Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010052. PubMed ID: 25173808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verapamil compared with nifedipine in the treatment of essential hypertension.
    Midtbø K; Hals O; van der Meer J
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S363-8. PubMed ID: 6184569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verapamil and 24-hour ambulatory blood pressure monitoring in essential hypertension.
    Zachariah PK; Sheps SG; Schirger A; Spiekerman RE; O'Brien PC; Simpson KK
    Am J Cardiol; 1986 Feb; 57(7):74D-79D. PubMed ID: 3953429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central hemodynamic changes of calcium antagonists at rest and during exercise in essential hypertension.
    Lund-Johansen P; Omvik P
    J Cardiovasc Pharmacol; 1987; 10 Suppl 1():S139-48. PubMed ID: 2442506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.